Welcome to the (U.S. Science) Apocalypse

By KIM BELLARD I’m starting to feel like I’m beating a dead horse, having already written a couple times recently about the Trump Administration’s attacks on science, but the hits just keep on coming. Last Friday, for example, not only did the Administration’s proposed 2026 budget slash National Science Foundation (NSF) funding by over 50%,…

Read More

Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With No Approved Meds

Biohaven’s troriluzole, which initially failed a pivotal study in spinocerebellar ataxia, is now being readied for an FDA submission in this rare neurodegenerative disease. The turnabout is based on positive results from a new study that incorporated real-world evidence. The post Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With…

Read More

KFF Health News’ ‘What the Health?’: On Autism, It’s the Secretary’s Word vs. CDC’s

The Host Emmarie Huetteman KFF Health News Emmarie Huetteman, senior editor, oversees a team of Washington reporters, as well as “Bill of the Month” and KFF Health News’ “What the Health?” She previously spent more than a decade reporting on the federal government, most recently covering surprise medical bills, drug pricing reform, and other health policy debates…

Read More

Cost impact of BTKi selection in Medicare patients with CLL

That is the title of my paper out today in the Journal of Comparative Effectiveness Research written with co-authors Adam Kittai, Dipen Patel, Nadine Zawadzki, Vikram Shetty, Yazan Barqawi, and Joanna Rhodes. The abstract is below. Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and…

Read More